• OPEN AN ACCOUNT
Indian Indices
Nifty
24,967.75 97.65
(0.39%)
Sensex
81,635.91 329.06
( 0.40%)
Bank Nifty
55,139.30 -10.10
( -0.02%)
Nifty IT
36,280.10 839.25
( 2.37%)
Global Indices
Nasdaq
45,658.64 852.13
(1.90%)
Dow Jones
6,488.44 97.27
(1.52%)
Hang Seng
42,789.96 156.67
(0.37%)
Nikkei 225
9,321.40 12.20
(0.13%)
Forex
USD-INR
87.17 0.12
(0.14%)
EUR-INR
101.39 0.01
(0.01%)
GBP-INR
117.16 -0.12
(-0.11%)
JPY-INR
0.59 0.00
(-0.18%)

EQUITY - MARKET SCREENER

Huhtamaki India Ltd
Industry :  Packaging
BSE Code
ISIN Demat
Book Value()
509820
INE275B01026
162.8195044
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
HUHTAMAKI
22.28
1624.1
EPS(TTM)
Face Value()
Div & Yield %
9.65
2
0.93
 

mangalam organics ltd
Concord Biotech gains after successful EU-GMP inspection at Limbassi facility
Aug 21,2025
The inspection was conducted by EU-GMP authorities from 18 August to 21 August 2025. The company stated that this milestone marks a significant achievement, as the successful outcome not only validates its commitment to global quality standards but also opens avenues to expand its presence in international markets.

The EU-GMP approval will allow Concord to explore commercial opportunities across multiple EU territories and other regulated geographies, strengthening its global footprint and supporting its growth strategy.

Concord added that the inspection outcome reaffirms its commitment to the highest standards of quality, safety, and regulatory compliance, highlighting its focus on operational excellence and alignment with international regulatory expectations.

Concord Biotech is involved in manufacturing fermentation and semi-synthetic biopharmaceutical APIs with immunosuppressants as its key therapeutic segment.

The company's consolidated net profit fell 26.1% to Rs 44.06 crore on a 5.5% decline in revenue from operations to Rs 203.99 crore in Q1 FY26 over Q1 FY25.